Compare EQ & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQ | STKS |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 74.3M |
| IPO Year | 2018 | N/A |
| Metric | EQ | STKS |
|---|---|---|
| Price | $1.53 | $2.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.00 | ★ $4.38 |
| AVG Volume (30 Days) | ★ 543.2K | 38.7K |
| Earning Date | 11-13-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,392,000.00 | ★ $820,588,000.00 |
| Revenue This Year | N/A | $23.94 |
| Revenue Next Year | N/A | $5.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 51.57 |
| 52 Week Low | $0.27 | $1.70 |
| 52 Week High | $2.35 | $5.26 |
| Indicator | EQ | STKS |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 47.99 |
| Support Level | $1.17 | $2.05 |
| Resistance Level | $1.32 | $2.26 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 94.12 | 11.67 |
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.